Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

eflornithine hydrochloride

&times

Overview

What is VANIQA?

VANIQA

 

Chemically, eflornithine hydrochloride is (±) -2-(difluoromethyl) ornithine monohydrochloride monohydrate, with the empirical formula CHFNO• HCl•HO, a molecular weight of 236.65 and the following structural formula:

Anhydrous eflornithine hydrochloride has an empirical formula CHFNO• HCl and a molecular weight of 218.65.

 

Other ingredients include: ceteareth-20; cetearyl alcohol; dimethicone; glyceryl stearate; methylparaben; mineral oil; PEG-100 stearate; phenoxyethanol; propylparaben; stearyl alcohol; and water.



What does VANIQA look like?



What are the available doses of VANIQA?

Sorry No records found.

What should I talk to my health care provider before I take VANIQA?

Sorry No records found

How should I use VANIQA?

Apply a thin layer of (eflornithine hydrochloride) cream, 13.9% to affected areas of the face and adjacent involved areas under the chin and rub in thoroughly. Do not wash treated area for at least 4 hours. Use twice daily at least 8 hours apart or as directed by a physician. The patient should continue to use hair removal techniques as needed in conjunction with . ( should be applied at least 5 minutes after hair removal.) Cosmetics or sunscreens may be applied over treated areas after cream has dried.


What interacts with VANIQA?

Sorry No Records found


What are the warnings of VANIQA?

Sorry No Records found


What are the precautions of VANIQA?

Sorry No Records found


What are the side effects of VANIQA?

Sorry No records found


What should I look out for while using VANIQA?

VANIQA

Discontinue use if hypersensitivity occurs.


What might happen if I take too much VANIQA?

Overdosage information with is unavailable. Given the low percutaneous penetration of this drug, overdosage via the topical route is not expected (see ). However, should very high topical doses (e.g., multiple tubes per day) or oral ingestion be encountered (a 30 g tube contains 4.2 g of eflornithine hydrochloride), the patient should be monitored, and appropriate supportive measures administered as necessary.

(Note: Use of an intravenous formulation of eflornithine hydrochloride at high doses (400 mg/kg/day or approximately 24 g/day) for the treatment of Trypanosoma brucei gambiense infection (African sleeping sickness) has been associated with adverse events and laboratory abnormalities. Adverse events in this setting have included hair loss, facial swelling, seizures, hearing impairment, stomach upset, loss of appetite, headache, weakness and dizziness. A variety of hematological toxicities, including anemia, thrombocytopenia and leukopenia have also been observed, but these were usually reversible upon discontinuation of treatment.)


How should I store and handle VANIQA?

StorageStore at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature] and protect from light.StorageStore at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature] and protect from light.VANIQAStorage: Revised: 1/2018Rx onlyMadison, NJ 07940© 2018 Allergan. All rights reserved.All trademarks are the property of their respective owners.73326US11-----Cut Here ----------------------------------------------------------------------------------------------------------------VANIQAStorage: Revised: 1/2018Rx onlyMadison, NJ 07940© 2018 Allergan. All rights reserved.All trademarks are the property of their respective owners.73326US11-----Cut Here ----------------------------------------------------------------------------------------------------------------VANIQAStorage: Revised: 1/2018Rx onlyMadison, NJ 07940© 2018 Allergan. All rights reserved.All trademarks are the property of their respective owners.73326US11-----Cut Here ----------------------------------------------------------------------------------------------------------------VANIQAStorage: Revised: 1/2018Rx onlyMadison, NJ 07940© 2018 Allergan. All rights reserved.All trademarks are the property of their respective owners.73326US11-----Cut Here ----------------------------------------------------------------------------------------------------------------VANIQAStorage: Revised: 1/2018Rx onlyMadison, NJ 07940© 2018 Allergan. All rights reserved.All trademarks are the property of their respective owners.73326US11-----Cut Here ----------------------------------------------------------------------------------------------------------------VANIQAStorage: Revised: 1/2018Rx onlyMadison, NJ 07940© 2018 Allergan. All rights reserved.All trademarks are the property of their respective owners.73326US11-----Cut Here ----------------------------------------------------------------------------------------------------------------VANIQAStorage: Revised: 1/2018Rx onlyMadison, NJ 07940© 2018 Allergan. All rights reserved.All trademarks are the property of their respective owners.73326US11-----Cut Here ----------------------------------------------------------------------------------------------------------------VANIQAStorage: Revised: 1/2018Rx onlyMadison, NJ 07940© 2018 Allergan. All rights reserved.All trademarks are the property of their respective owners.73326US11-----Cut Here ----------------------------------------------------------------------------------------------------------------VANIQAStorage: Revised: 1/2018Rx onlyMadison, NJ 07940© 2018 Allergan. All rights reserved.All trademarks are the property of their respective owners.73326US11-----Cut Here ----------------------------------------------------------------------------------------------------------------VANIQAStorage: Revised: 1/2018Rx onlyMadison, NJ 07940© 2018 Allergan. All rights reserved.All trademarks are the property of their respective owners.73326US11-----Cut Here ----------------------------------------------------------------------------------------------------------------VANIQAStorage: Revised: 1/2018Rx onlyMadison, NJ 07940© 2018 Allergan. All rights reserved.All trademarks are the property of their respective owners.73326US11-----Cut Here ----------------------------------------------------------------------------------------------------------------VANIQAStorage: Revised: 1/2018Rx onlyMadison, NJ 07940© 2018 Allergan. All rights reserved.All trademarks are the property of their respective owners.73326US11-----Cut Here ----------------------------------------------------------------------------------------------------------------VANIQAStorage: Revised: 1/2018Rx onlyMadison, NJ 07940© 2018 Allergan. All rights reserved.All trademarks are the property of their respective owners.73326US11-----Cut Here ----------------------------------------------------------------------------------------------------------------VANIQAStorage: Revised: 1/2018Rx onlyMadison, NJ 07940© 2018 Allergan. All rights reserved.All trademarks are the property of their respective owners.73326US11-----Cut Here ----------------------------------------------------------------------------------------------------------------VANIQAStorage: Revised: 1/2018Rx onlyMadison, NJ 07940© 2018 Allergan. All rights reserved.All trademarks are the property of their respective owners.73326US11-----Cut Here ----------------------------------------------------------------------------------------------------------------


&times

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

There are no studies examining the inhibition of the enzyme ornithine decarboxylase (ODC) in human skin following the application of topical eflornithine. However, there are studies in the literature that report the inhibition of ODC activity in skin following oral eflornithine. It is postulated that topical eflornithine hydrochloride irreversibly inhibits skin ODC activity. This enzyme is necessary in the synthesis of polyamines. Animal data indicate that inhibition of ornithine decarboxylase inhibits cell division and synthetic functions, which affect the rate of hair growth. (eflornithine hydrochloride) cream, 13.9% has been shown to retard the rate of hair growth in non-clinical and clinical studies.

Non-Clinical Toxicology
VANIQA

Discontinue use if hypersensitivity occurs.

Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patients receiving such agents.

Clindamycin is metabolized predominantly by CYP3A4, and to a lesser extent by CYP3A5, to the major metabolite clindamycin sulfoxide and minor metabolite N-desmethylclindamycin. Therefore inhibitors of CYP3A4 and CYP3A5 may increase plasma concentrations of clindamycin and inducers of these isoenzymes may reduce plasma concentrations of clindamycin. In the presence of strong CYP3A4 inhibitors, monitor for adverse reactions. In the presence of strong CYP3A4 inducers such as rifampicin, monitor for loss of effectiveness.

In vitro

Array

For external use only.

Transient stinging or burning may occur when applied to abraded or broken skin.

Adverse events reported for most body systems occurred at similar frequencies in  (eflornithine hydrochloride) cream, 13.9% and vehicle control groups. The most frequent adverse events related to treatment with were skin-related. The following table notes the percentage of adverse events associated with the use of or its vehicle that occurred at greater than 1% in both the vehicle-controlled studies and the open-label safety studies up to 1 year of continuous use.

Treatment-related skin adverse events that occurred in less than 1% of the subjects treated with are: bleeding skin, cheilitis, contact dermatitis, swelling of lips, herpes simplex, numbness, and rosacea.

Adverse events were primarily mild in intensity and generally resolved without medical treatment or discontinuation of . Only 2% of subjects discontinued studies due to an adverse event related to use of .

&times

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

&times

Review

Rate this treatment and share your opinion


Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

This medication has worked for me.




This medication has been easy for me to use.




Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
&times

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
&times

Tips

Tips

&times

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).